We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.7B
AUM Growth
+$120M
Cap. Flow
-$25.9M
Cap. Flow %
-0.96%
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$17.5M
2
NVRO
NEVRO CORP.
NVRO
+$15.6M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$14.2M
4
NVS icon
Novartis
NVS
+$11.9M
5
BIIB icon
Biogen
BIIB
+$11.8M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.3M
2
MOH icon
Molina Healthcare
MOH
+$18.4M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.9M
4
PFE icon
Pfizer
PFE
+$11.2M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.69%
2 Real Estate 3.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNK
101
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$2.77M 0.1%
61,900
– –
AXDX
102
DELISTED
Accelerate Diagnostics
AXDX
$2.73M 0.1%
10,000
– –
MNTA
103
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.58M 0.1%
152,900
-351,500
-70% -$5.35M
HR
104
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.32M 0.09%
68,000
– –
DBVT
105
DBV Technologies
DBVT
$817M
$2.28M 0.08%
6,380
-180
-3% -$61.5K
CDTX
106
DELISTED
Cidara Therapeutics
CDTX
$2.15M 0.08%
14,324
– –
CYH icon
107
Community Health Systems
CYH
$391M
$2.03M 0.08%
203,935
– –
IPXL
108
DELISTED
Impax Laboratories, Inc.
IPXL
$2M 0.07%
124,335
– –
ORKA
109
Oruka Therapeutics
ORKA
$5.9B
$1.99M 0.07%
3,756
– –
TRIL
110
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.98M 0.07%
+500,000
New +$2.77M
HZNP
111
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.93M 0.07%
162,900
– –
NSTG
112
DELISTED
NanoString Technologies, Inc.
NSTG
$1.88M 0.07%
113,500
– –
XLRN
113
DELISTED
Acceleron Pharma
XLRN
$1.81M 0.07%
59,654
+5,204
+10% +$151K
JUNO
114
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.7M 0.06%
56,900
– –
NBRV
115
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.68M 0.06%
597
-336
-36% -$867K
FOLD
116
DELISTED
Amicus Therapeutics
FOLD
$1.62M 0.06%
160,730
-258,000
-62% -$2.08M
WELL icon
117
Welltower
WELL
$170B
$1.6M 0.06%
21,400
– –
ARGX icon
118
argenx
ARGX
$54.6B
$1.59M 0.06%
+75,000
New +$1.56M
QURE icon
119
uniQure
QURE
$2.93B
$1.49M 0.06%
241,021
– –
DOC icon
120
Healthpeak Properties
DOC
$15.2B
$1.45M 0.05%
45,500
– –
LKFT
121
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$1.45M 0.05%
19,000
-96,738
-84% -$8.14M
ONCE
122
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.45M 0.05%
24,300
– –
HR icon
123
Healthcare Realty
HR
$7.46B
$1.43M 0.05%
46,000
– –
BLUE
124
DELISTED
bluebird bio
BLUE
$1.39M 0.05%
1,025
-2,784
-73% -$3.36M
CHRS icon
125
Coherus Oncology
CHRS
$227M
$1.29M 0.05%
90,000
– –
2 3 4
5
6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Tekla Capital Management held 152 positions worth $2.7B, up 4.7% from $2.58B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q2 2017 filing shows 13 new, 22 increased, 27 reduced and 8 closed positions. Its largest new stake was NEVRO CORP.: 194,621 shares worth $14.5M. The largest sale was Vertex Pharmaceuticals, an estimated $28.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2017 buy was NEVRO CORP.: 194,621 shares worth $14.5M.
  • Tekla Capital Management added most to Merck in Q2 2017, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $28.3M.
  • Tekla Capital Management fully exited Molina Healthcare in Q2 2017, selling an estimated $18.4M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.7B portfolio in Q2 2017.
  • Tekla Capital Management opened 13 new positions and closed 8 in Q2 2017.
  • Tekla Capital Management's portfolio value rose 4.7% quarter-over-quarter to $2.7B.

Based on Tekla Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.